Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Smith & Nephew buys Rotation Medical for US$125mln

Smith & Nephew will pay US$125mln for Rotation Medical plus up to a further US$85mln over the next five years, contingent on financial performance
shoulder
Rotation’s rotator cuff technology complements Smith & Nephew's shoulder repair technologies

Medical equipment group Smith & Nephew (LON:SN.) has completed the acquisition of Rotation Medical Inc., a US-based developer of tissue-regeneration technology to treat rotator-cuff disease.

Smith & Nephew is to pay US$125mln for Rotation plus up to a further US$85mln over the next five years, contingent on financial performance.

READ: Smith & Nephew says full year growth to be at lower end of guidance range

The company said Rotation’s rotator cuff system is “highly complementary” to its existing portfolio of shoulder repair technologies to supplement repairs of more complex tears.

The procedure involves using a bioinductive implant that helps tendons heal by inducing growth of new tendon-like tissue, enhancing the body’s natural healing response.

It helps prevent tear progression and reduce the incidence of re-tears. 

READ: Smith & Nephew chief executive Olivier Bohuon to step down next year

Smith&Nephew said there are more than 650,000 rotator cuff procedures per year in the US growing at a rate of 5-6% per annum.  The cuff system will be sold through Smith & Nephew's larger sports medicine sales force and the integrated Rotation Medical sales team. 

View full SN. profile View Profile

Smith & Nephew PLC Timeline

Related Articles

test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”
cancer cells
11:02
The AIM-listed group, whose focus is cancer and autoimmune diseases, licensed its SRA737 to US firm Sierra Oncology just over a year ago
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use